BASi has expanded its bioanalytical services and now offers ligand binding assays (LBA) for macromolecular drug therapeutics, immunogenicity screening, and biomarkers in biological matrices. Enzyme immunoassays (EIA) or enzyme-linked immunosorbent assay (ELISA)-based applications are the primary tools for these services.
Recognizing the demand for large-molecule drug development, BASi partnered with companies developing compounds in areas such as monoclonal antibody therapeutics, in order to provide biopharmaceutical companies with data that enables them to make accurate decisions on the drug development program. Large molecule biomarkers inform therapeutic decision makers on the viability of an applicant’s drug and help bring new medicines to market faster. The effective use of information based on biomarker analysis potentially leads to faster decisions and reduces late-stage failures.
